ALNY:NGS-Alnylam Pharmaceuticals Inc. (USD)

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing

USD 278.76

Change

0.00 (0.00)%

Market Cap

USD 3.92B

Volume

0.92M

Analyst Target

USD 166.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Alnylam Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in developing novel therapeutics based on RNA interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for regulating the expression of specific genes.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-25 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 104.84B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 78.92B
ARGX argenx NV ADR

N/A

USD 39.62B
MRNA Moderna Inc

N/A

USD 18.29B
RPRX Royalty Pharma Plc

N/A

USD 18.12B
SMMT Summit Therapeutics PLC

N/A

USD 17.52B
UTHR United Therapeutics Corporatio..

N/A

USD 15.91B
INCY Incyte Corporation

N/A

USD 13.41B
BMRN Biomarin Pharmaceutical Inc

N/A

USD 12.74B
INSM Insmed Inc

N/A

USD 12.50B

ETFs Containing ALNY

MSGR 6.64 % 0.00 %

N/A

N/A
CURE:XETRA VanEck Genomics and Healt.. 5.76 % 0.00 %

N/A

N/A
CURG:LSE VanEck Genomics and Healt.. 4.94 % 0.00 %

N/A

USD 4.94M
BBH VanEck Biotech ETF 4.13 % 0.35 %

N/A

USD 0.40B
GNOG:LSE Global X Genomics & Biote.. 3.90 % 0.00 %

N/A

USD 9.83M
BIOT:SW L&G Pharma Breakthrough U.. 3.89 % 0.00 %

N/A

N/A
BTEC:SW iShares Nasdaq US Biotech.. 3.20 % 0.00 %

N/A

N/A
JNDQ:AU BETAJNDQ ETF UNITS 2.14 % 0.00 %

N/A

N/A
EQQJ:SW Invesco NASDAQ Next Gener.. 2.11 % 0.00 %

N/A

N/A
EQQJ:XETRA Invesco NASDAQ Next Gener.. 2.10 % 0.00 %

N/A

USD 0.05B
EQJS:LSE Invesco NASDAQ Next Gener.. 2.09 % 0.00 %

N/A

USD 0.05B
EQQJ:LSE Invesco NASDAQ Next Gener.. 2.02 % 0.00 %

N/A

N/A
TMFX Motley Fool Next Index ET.. 1.51 % 0.00 %

N/A

USD 0.03B
WELP:LSE HAN-GINS Indxx Healthcare.. 1.36 % 0.00 %

N/A

N/A
THNZ:XETRA L&G Global Thematic ESG E.. 0.87 % 0.00 %

N/A

N/A
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

N/A

USD 0.06B
FFTY Innovator IBD® 50 ETF 0.00 % 0.80 %

N/A

N/A
IBB iShares Biotechnology ETF 0.00 % 0.47 %

N/A

USD 6.25B
LABS 0.00 % 0.45 %

N/A

N/A
LABU Direxion Daily S&P Biotec.. 0.00 % 1.14 %

N/A

USD 0.77B
QRH:CA 0.00 % 1.20 %

N/A

N/A
RBUS 0.00 % 0.30 %

N/A

N/A
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

N/A
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

N/A
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

N/A
XBI SPDR® S&P Biotech ETF 0.00 % 0.35 %

N/A

N/A
2B70:F iShares NASDAQ US Biotech.. 0.00 % 0.00 %

N/A

USD 0.52B
2B70:XETRA iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

USD 0.52B
ZGEN:CA 0.00 % 0.00 %

N/A

N/A
GERM 0.00 % 0.00 %

N/A

N/A
QQQJ Invesco NASDAQ Next Gen 1.. 0.00 % 0.00 %

N/A

USD 0.66B
QQQN 0.00 % 0.00 %

N/A

N/A
IBBQ Invesco Nasdaq Biotechnol.. 0.00 % 0.00 %

N/A

USD 0.04B
XGES:LSE Xtrackers MSCI Genomic He.. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 18.47% 83% B 89% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 18.47% 83% B 89% A-
Trailing 12 Months  
Capital Gain 55.19% 84% B 86% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 55.19% 84% B 86% B+
Trailing 5 Years  
Capital Gain 138.20% 90% A- 89% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 138.20% 90% A- 88% B+
Average Annual (5 Year Horizon)  
Capital Gain 15.12% 61% D- 68% D+
Dividend Return 15.12% 61% D- 66% D+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 27.81% 89% A- 66% D+
Risk Adjusted Return 54.38% 95% A 80% B-
Market Capitalization 3.92B 99% N/A 97% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A
Price/Book Ratio 933.97 0% 0%
Price / Cash Flow Ratio 290.12 1% 1%
Price/Free Cash Flow Ratio 204.85 1% 2%
Management Effectiveness  
Return on Equity -1,500.66% 5% 2%
Return on Invested Capital -34.83% 67% 29%
Return on Assets -2.92% 93% 46%
Debt to Equity Ratio -462.63% 98% 98%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.